MrKeith的个人主页 - 老虎社区

MrKeith

MrKeith

暂无个人介绍

IP属地：未知

2关注

1粉丝

0主题

0勋章

2021-12-16

Bad news?

抱歉，原内容已删除

2021-12-14

Very good read. Thanks

昨夜今晨：超级央行周压力显现！三大股指跌幅接近1%

2021-12-13

Interesting. I will research more on these retail giant… did they soar due to recent pandemic? Is ita long term growth? Shopify: they’re many onlinegiants emerging, including powerhouse Taobao, JD, etc. Will they hold their fort for long? Overall agood read. Thanks for sharing.

3 High-Growth Stocks That Could Be Worth $1 Trillion in 10 Years – or Sooner

2021-12-11

Merck would be a better option comparing to Amgen. They diversified their products.

Is It Time to Buy the Dow's 3 Worst Performing Stocks This Year?

2021-12-10

Good news to buy?

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4092093145464560","uuid":"4092093145464560","gmtCreate":1628990417993,"gmtModify":1639100348329,"name":"MrKeith","pinyin":"mrkeith","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/460dea2188efdfc37ad3bbaf86f6b649","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":2,"tweetSize":5,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":690092052,"gmtCreate":1639611965754,"gmtModify":1639611965754,"author":{"id":"4092093145464560","authorId":"4092093145464560","name":"MrKeith","avatar":"https://static.tigerbbs.com/460dea2188efdfc37ad3bbaf86f6b649","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4092093145464560","authorIdStr":"4092093145464560"},"themes":[],"htmlText":"Bad news?","listText":"Bad news?","text":"Bad news?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690092052","repostId":"2191499479","repostType":2,"isVote":1,"tweetType":1,"viewCount":889,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604791287,"gmtCreate":1639444098079,"gmtModify":1639444098174,"author":{"id":"4092093145464560","authorId":"4092093145464560","name":"MrKeith","avatar":"https://static.tigerbbs.com/460dea2188efdfc37ad3bbaf86f6b649","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4092093145464560","authorIdStr":"4092093145464560"},"themes":[],"htmlText":"Very good read. Thanks","listText":"Very good read. Thanks","text":"Very good read. Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604791287","repostId":"1168636209","repostType":2,"repost":{"id":"1168636209","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639439604,"share":"https://www.laohu8.com/m/news/1168636209?lang=&edition=full","pubTime":"2021-12-14 07:53","market":"sh","language":"zh","title":"昨夜今晨：超级央行周压力显现！三大股指跌幅接近1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1168636209","media":"老虎资讯综合","summary":"摘要：①联储会议前美股收跌，道指下跌0.89%；②热门中概股收盘大多走低，瑞幸粉单跌近8%；③加速减码+预告加息，美联储可能上演历史罕见的鹰派转变；④英国出现首例奥密克戎死亡病例。\n\n海外市场\n1、联","content":"<blockquote>\n 摘要：①联储会议前美股收跌，道指下跌0.89%；②热门中概股收盘大多走低，瑞幸粉单跌近8%；③加速减码+预告加息，美联储可能上演历史罕见的鹰派转变；④英国出现首例奥密克戎死亡病例。\n</blockquote>\n<p>海外市场</p>\n<p>1、联储会议前美股收跌 道指下跌320点</p>\n<p>周一(12月13日)，美股收盘走低，<a href=\"https://laohu8.com/S/CCL.UK\">嘉年华公司</a>和几家航空公司的股价暴跌，原因是在本周晚些时候美联储召开会议之前投资者对奥密克戎变种忧心忡忡。</p>\n<p>标准普尔500指数收盘下跌0.91%，较盘中高点下跌1.6%左右。受波音公司股价下跌3.7%的拖累，道琼斯指数下跌道指跌320.04点或0.89%。以科技股为主的纳斯达克综合指数下跌1.39%。</p>\n<p>2、热门中概股周一收盘大多走低 瑞幸粉单跌近8%</p>\n<p>热门中概股周一收盘大多走低，瑞幸粉单跌近8%，消息面，<a href=\"https://laohu8.com/S/LUCKIN\">瑞幸咖啡</a>召开股东大会，防止前造假管理层获得股权。</p>\n<p>热门中概股大多下跌。<a href=\"https://laohu8.com/S/RENN\">人人网</a>ADR跌超17%，<a href=\"https://laohu8.com/S/BEKE\">贝壳</a>跌约15%，<a href=\"https://laohu8.com/S/NTES\">网易</a>有道跌超14%，<a href=\"https://laohu8.com/S/LK\">瑞幸咖啡</a>跌近8%，<a href=\"https://laohu8.com/S/BILI\">哔哩哔哩</a>跌超6%，<a href=\"https://laohu8.com/S/TME\">腾讯音乐</a>、<a href=\"https://laohu8.com/S/EDU\">新东方</a>、<a href=\"https://laohu8.com/S/DOYU\">斗鱼</a>、<a href=\"https://laohu8.com/S/IQ\">爱奇艺</a>跌超4%，<a href=\"https://laohu8.com/S/PDD\">拼多多</a>、<a href=\"https://laohu8.com/S/BIDU\">百度</a>、<a href=\"https://laohu8.com/S/XPEV\">小鹏汽车</a>、<a href=\"https://laohu8.com/S/LI\">理想汽车</a>、<a href=\"https://laohu8.com/S/03333\">中国恒大</a>粉单跌超3%，<a href=\"https://laohu8.com/S/BABA\">阿里巴巴</a>、<a href=\"https://laohu8.com/S/JD\">京东</a>、<a href=\"https://laohu8.com/S/HUYA\">虎牙</a>跌超2%，<a href=\"https://laohu8.com/S/NIO\">蔚来</a>汽车跌超1%，<a href=\"https://laohu8.com/S/00700\">腾讯</a>ADR跌近0.8%，而<a href=\"https://laohu8.com/S/DDL\">叮咚</a>买菜收涨超18%，<a href=\"https://laohu8.com/S/NCTY\">第九城市</a>近10%，<a href=\"https://laohu8.com/S/ZME\">掌门教育</a>涨超4%，图森未来涨超1%。</p>\n<p>3、本周多国央行会议在即 欧股再次下滑</p>\n<p>欧洲股市周一(12月13日)下滑，泛欧斯托克600指数收盘跌幅0.5%，大多数板块都在下跌。投资者对奥密克戎病毒变体的发展做出反应，并等待本周主要央行的货币政策决定。这将是货币政策的重要一周，美国联邦储备委员会、日本央行、英国央行和欧洲央行都将在本周举行会议并作出货币政策决定。</p>\n<p>泛欧斯托克600指数收盘下跌2.03点，跌幅0.54%，报473.53点；德国DAX30指数收盘下跌2.91点，跌幅0.02%，报15620.40点。</p>\n<p>4、Omicron再次引发需求担忧 油价下跌</p>\n<p>交易商权衡Omicron变体的风险，而欧佩克上调了对全球原油需求的预测。周一(12月13日)，油价下跌。</p>\n<p>截至收盘，美国WTI原油期货下跌37美分，跌幅0.52%，报71.30美元/桶；布伦特期货下跌66美分，跌幅0.88%，报74.49美元/桶。</p>\n<p>5、年终大考在即黄金顽强走高 金价或很快突破1800美元大关</p>\n<p>周一(12月13日)，金价小幅走高，因投资者在本周关键的央行会议前增持仓位，美联储可能会发出信号，表明其可能会以什么速度退出大流行时期的经济支持措施。</p>\n<p>美市尾盘，现货黄金收报1786.48美元/盎司，上涨3.79美元或0.21%，日内最高触及1790.99美元高点，最低触及1781.37美元。上周，现货黄金收跌0.52美元或0.03%。</p>\n<p>国际宏观</p>\n<p>1、加速减码+预告加息 美联储可能上演历史罕见的鹰派转变</p>\n<p>经济学家预计，美联储官员本周将加快收缩购债步伐，并发出2022年加息的信号，在1980年代以来最强通胀面前上演历史性的政策转变。</p>\n<p>超过一半的受访者预计，美联储周三结束两天政策会议后发布的季度预测将显示，18位官员的中值预测是明年加息两次。这与他们9月份的预测相比有变化。当时，决策者在2022年或2023年首次加息的预测上平分秋色。“这将是点阵图历史上最大的鹰派转变，”Macropolicy Perspectives高级经济学家Laura Rosner-Warburton表示。美联储自2012年开始发布利率预测的点阵图。美联储主席杰罗姆·鲍威尔在11月30日对议员们表示，考虑加快减码进程，比原计划(2022年中)提前几个月结束可能是合适的。</p>\n<p>2、纽约联储调查显示：消费者对未来一年的通胀预期升至6%的新高</p>\n<p>纽约联邦储备银行最新消费者调查显示，美国消费者对未来一年的通胀预期升至6%的新高。调查还显示，三年通胀预期自6月以来首次下降，达到4%，主要是受到无大学学历受访者的预期推动。然而，无论是短期还是长期，通胀的不确定性水平都在上升，并且都达到了历史新高。</p>\n<p>3、牛津大学：omicron毒株能削弱两针<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>或<a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>疫苗的保护力</p>\n<p>研究人员发现，正如人们所担忧的一样，omicron变异株削弱了辉瑞和阿斯利康两剂新冠疫苗所能提供的保护力，增加了接种者感染风险。牛津大学研究人员周一在一份报告中表示，在对接种辉瑞或阿斯利康疫苗的人采集的血液样本中，经检测新毒株omicron令中和抗体大幅减少，尤其是和德尔塔毒株相比，降幅很明显。</p>\n<p>4、约翰逊证实：英国已出现奥密克戎死亡病例 另有10人住院治疗</p>\n<p>英国首相鲍里斯·约翰逊周一(12月13日)证实，英国至少有一名感染新冠病毒奥密克戎毒株的患者死亡。</p>\n<p>约翰逊在访问伦敦帕丁顿附近的一家疫苗接种诊所时对记者说：“有几位奥密克戎感染者正在住院治疗。不幸的是，至少有一名患者被证实死于奥密克戎。”</p>\n<p>5、美国累计新冠肺炎确诊病例超5000万例</p>\n<p>当地时间13日，根据美国约翰斯·霍普金斯大学数据，截至美东时间当天14时22分(北京时间12月14日凌晨3时22分)，美国累计确诊新冠肺炎病例超5000万例，达50009507例；累计死亡病例达797916例。</p>\n<p>6、七国集团财长承诺解决供应链问题并避免未来重演</p>\n<p>七国集团财长承诺加强合作，以解决造成商品短缺和通胀飙升的全球供应链问题。由于运输问题导致供应中断，零部件制成品短缺以及疫情造成能源价格上涨，全球消费者价格都在飙升。美国通胀率已触及1982年以来的最高水平，欧元区通胀率达到了创纪录的4.9%。</p>\n<p>7、欧佩克月报：上调明年一季度全球原油需求预期 奥密克戎影响有限</p>\n<p>欧佩克周一表示，奥密克戎变体对全球原油市场的影响将是有限的，各国政府和企业现在已经适应且能够更好地应对新冠疫情。此外，欧佩克大幅上调了明年第一季度的原油需求预期。在其备受关注的最新月报中，欧佩克将2022年第一季度全球原油需求预期上调111万桶/日，至9913万桶/日； 将2022年全球需求预期上调20万桶/日，至2880万桶/日。</p>\n<p>8、加拿大央行重申2%通胀目标 将把就业最大化纳入使命范围</p>\n<p>加拿大央行将在未来五年维持2%的通胀目标，但允许小幅超过目标以支持可持续的就业最大化。在周一与加拿大政府联合发布的声明中，加拿大央行增加了一项新要求，即必要情况下，官员将使用1%-3%的控制区间来“继续”支持就业水平，但同时强调以通胀目标为首要。</p>\n<p>市场观点</p>\n<p>1、<a href=\"https://laohu8.com/NW/2191735989\" target=\"_blank\">美股瑟瑟发抖：经济学家普遍预期本周美联储将发布“最鹰点阵图”</a></p>\n<p>根据美国当地媒体周一发布的经济学家调查，眼下市场普遍预期美联储官员们本周将明确给出2022年加息的信号，同时加快缩减债券购买规模的速度。</p>\n<p>这项调查在今年12月3日至8日期间进行，值得一提的是，参与调查的49名经济学家中有超过半数认为，18位FOMC委员的中位点阵图预期将达到明年两次加息，这也与九月FOMC经济前瞻形成鲜明反差，当时18名委员中预测2022和2023年开始加息的各占一半。</p>\n<p>2、小摩预计美失业率明年将降至3%左右 奥密克戎是就业市场主要风险</p>\n<p><a href=\"https://laohu8.com/S/JPM\">摩根大通</a>首席美国经济学家Michael Feroli认为，2022年美国失业率将下降。“我认为到2022年底可以看到失业率在3%左右，”Feroli称。“过去五个月的失业率下降幅度令人深刻印象。我们预计下降速度会放缓，但很快就会降至4%以下。”在Feroli看来，随着雇主寻找人才以推动企业从疫情中复苏，就业市场可能会以良好的势头进入2022年。</p>\n<p>公司新闻</p>\n<p>1、<a href=\"https://laohu8.com/NW/2191988721\" target=\"_blank\">特斯拉CEO埃隆·马斯克当选时代杂志2021年度风云人物</a></p>\n<p>特斯拉CEO埃隆·马斯克(Elon Musk)今日被美国《时代》杂志评为“2021年度风云人物”。</p>\n<p>《时代》杂志称，作为世界上最富有的人，他没有房子，最近一直在抛售财产。他将卫星送入轨道，并利用<a href=\"https://laohu8.com/S/000591\">太阳能</a>服务千家万户。他驾驶着一辆自己制造的汽车，不需要汽油，也几乎不需要司机。他的手指一挥，股市就会暴涨或暴跌。他的每一句话都被一大群粉丝挂在嘴边。当他把业务推向全球时，还梦想着移民火星。</p>\n<p>2、<a href=\"https://laohu8.com/NW/2191828979\" target=\"_blank\">苹果周一收盘跌超2% 创11月26日以来最大单日跌幅</a></p>\n<p>苹果公司股价周一收盘大跌，未能跨越成为全球首家市值达到3万亿美元公司的里程碑。截至周一收盘，苹果公司股价下跌2.07%，报175.74美元，创11月26日以来最大单日跌幅，市值2.88万亿美元。该公司股价周一盘中最高达到182.13美元，市值最高达到2.987万亿美元。苹果公司市值要超越3万亿美元大关，股价需要达到182.86美元。</p>\n<p>3、<a href=\"https://laohu8.com/NW/2191881989\" target=\"_blank\">辉瑞溢价100%收购阿里那制药 交易总价值接近67亿美元</a></p>\n<p>当地时间周一，全球医药龙头辉瑞发布公告，将以高额溢价收购创新药开发公司阿里那(Arena)制药，后者在免疫炎症领域拥有多款在研产品。</p>\n<p>根据公告，辉瑞将以每股100美元的价格展开纯现金收购，这一价格较阿里那制药上周五收盘价49.94美元溢价达100%。受此消息影响，截至发稿阿里那股价上涨接近85%至92美元。在新冠疫苗和口服药领域取得科研和商业的双重成功后，财大气粗的辉瑞在公告中表示，这笔交易对阿里那制药的股权估值为67亿美元，公司手头的现金就足以支付。这项交易预期在2022年上半年完成。</p>\n<p>4、<a href=\"https://laohu8.com/NW/2191989094\" target=\"_blank\">哈雷电动摩托车部门拟以SPAC上市谋转型 估值17.7亿美元</a></p>\n<p>美东时间时间12月13日周一，<a href=\"https://laohu8.com/S/HOG\">哈雷戴维森</a>Harley Davidson公司表示，其电动摩托车部门LiveWire将通以SPAC Special Purpose Acquisition Corporation合并的方式上市，预计合并后的公司估值为17.7亿美元。</p>\n<p>5、<a href=\"https://laohu8.com/NW/2191098483\" target=\"_blank\">英特尔寻求扩大芯片产能 计划投资71亿美元在马来西亚设新厂</a></p>\n<p>据马来西亚政府机构周一(12月13日)称，芯片制造商英特尔公司(Intel)计划在马来西亚投资300亿林吉特(合71亿美元)建立最先进的半导体生产设施，扩大其生产能力。与此同时，美国政府正在积极推动全球各大半导体企业在美设厂，欲将芯片供应链留在美国国内。</p>\n<p>7、<a href=\"https://laohu8.com/NW/2191763986\" target=\"_blank\">瑞银集团协助客户逃税罪名成立 被罚约18亿欧元</a></p>\n<p>法国巴黎一家上诉法院判决瑞银(UBS.N)协助法国客户逃税的罪名成立，但将处罚金额从45亿欧元降至约18亿欧元。该法院表示，瑞银集团在2004年至2012年期间系统地帮助法国客户逃税，引诱他们将钱藏在瑞士。该案最初于2019年宣判，瑞银集团被罚款37亿欧元，外加8亿欧元的损害赔偿及利息。之后，瑞银集团对这一判决提出上诉。</p>\n<p>8、<a href=\"https://laohu8.com/NW/2191917607\" target=\"_blank\">瑞幸咖啡召开股东大会 防止前造假管理层获得股权</a></p>\n<p>12月13日，瑞幸咖啡发布公告称，瑞幸咖啡股东大会已于2021年12月11日召开。会议上通过了提交股东批准的拟议决议，以及公司第五次修订及重述的组织章程大纲及细则。这些拟议措施是为限制前造假管理层获得公司股权的能力，以此限制他们以直接或间接的方式影响公司，从而保护公司的长期生存能力。</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>昨夜今晨：超级央行周压力显现！三大股指跌幅接近1%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n昨夜今晨：超级央行周压力显现！三大股指跌幅接近1%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-12-14 07:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<blockquote>\n 摘要：①联储会议前美股收跌，道指下跌0.89%；②热门中概股收盘大多走低，瑞幸粉单跌近8%；③加速减码+预告加息，美联储可能上演历史罕见的鹰派转变；④英国出现首例奥密克戎死亡病例。\n</blockquote>\n<p>海外市场</p>\n<p>1、联储会议前美股收跌 道指下跌320点</p>\n<p>周一(12月13日)，美股收盘走低，<a href=\"https://laohu8.com/S/CCL.UK\">嘉年华公司</a>和几家航空公司的股价暴跌，原因是在本周晚些时候美联储召开会议之前投资者对奥密克戎变种忧心忡忡。</p>\n<p>标准普尔500指数收盘下跌0.91%，较盘中高点下跌1.6%左右。受波音公司股价下跌3.7%的拖累，道琼斯指数下跌道指跌320.04点或0.89%。以科技股为主的纳斯达克综合指数下跌1.39%。</p>\n<p>2、热门中概股周一收盘大多走低 瑞幸粉单跌近8%</p>\n<p>热门中概股周一收盘大多走低，瑞幸粉单跌近8%，消息面，<a href=\"https://laohu8.com/S/LUCKIN\">瑞幸咖啡</a>召开股东大会，防止前造假管理层获得股权。</p>\n<p>热门中概股大多下跌。<a href=\"https://laohu8.com/S/RENN\">人人网</a>ADR跌超17%，<a href=\"https://laohu8.com/S/BEKE\">贝壳</a>跌约15%，<a href=\"https://laohu8.com/S/NTES\">网易</a>有道跌超14%，<a href=\"https://laohu8.com/S/LK\">瑞幸咖啡</a>跌近8%，<a href=\"https://laohu8.com/S/BILI\">哔哩哔哩</a>跌超6%，<a href=\"https://laohu8.com/S/TME\">腾讯音乐</a>、<a href=\"https://laohu8.com/S/EDU\">新东方</a>、<a href=\"https://laohu8.com/S/DOYU\">斗鱼</a>、<a href=\"https://laohu8.com/S/IQ\">爱奇艺</a>跌超4%，<a href=\"https://laohu8.com/S/PDD\">拼多多</a>、<a href=\"https://laohu8.com/S/BIDU\">百度</a>、<a href=\"https://laohu8.com/S/XPEV\">小鹏汽车</a>、<a href=\"https://laohu8.com/S/LI\">理想汽车</a>、<a href=\"https://laohu8.com/S/03333\">中国恒大</a>粉单跌超3%，<a href=\"https://laohu8.com/S/BABA\">阿里巴巴</a>、<a href=\"https://laohu8.com/S/JD\">京东</a>、<a href=\"https://laohu8.com/S/HUYA\">虎牙</a>跌超2%，<a href=\"https://laohu8.com/S/NIO\">蔚来</a>汽车跌超1%，<a href=\"https://laohu8.com/S/00700\">腾讯</a>ADR跌近0.8%，而<a href=\"https://laohu8.com/S/DDL\">叮咚</a>买菜收涨超18%，<a href=\"https://laohu8.com/S/NCTY\">第九城市</a>近10%，<a href=\"https://laohu8.com/S/ZME\">掌门教育</a>涨超4%，图森未来涨超1%。</p>\n<p>3、本周多国央行会议在即 欧股再次下滑</p>\n<p>欧洲股市周一(12月13日)下滑，泛欧斯托克600指数收盘跌幅0.5%，大多数板块都在下跌。投资者对奥密克戎病毒变体的发展做出反应，并等待本周主要央行的货币政策决定。这将是货币政策的重要一周，美国联邦储备委员会、日本央行、英国央行和欧洲央行都将在本周举行会议并作出货币政策决定。</p>\n<p>泛欧斯托克600指数收盘下跌2.03点，跌幅0.54%，报473.53点；德国DAX30指数收盘下跌2.91点，跌幅0.02%，报15620.40点。</p>\n<p>4、Omicron再次引发需求担忧 油价下跌</p>\n<p>交易商权衡Omicron变体的风险，而欧佩克上调了对全球原油需求的预测。周一(12月13日)，油价下跌。</p>\n<p>截至收盘，美国WTI原油期货下跌37美分，跌幅0.52%，报71.30美元/桶；布伦特期货下跌66美分，跌幅0.88%，报74.49美元/桶。</p>\n<p>5、年终大考在即黄金顽强走高 金价或很快突破1800美元大关</p>\n<p>周一(12月13日)，金价小幅走高，因投资者在本周关键的央行会议前增持仓位，美联储可能会发出信号，表明其可能会以什么速度退出大流行时期的经济支持措施。</p>\n<p>美市尾盘，现货黄金收报1786.48美元/盎司，上涨3.79美元或0.21%，日内最高触及1790.99美元高点，最低触及1781.37美元。上周，现货黄金收跌0.52美元或0.03%。</p>\n<p>国际宏观</p>\n<p>1、加速减码+预告加息 美联储可能上演历史罕见的鹰派转变</p>\n<p>经济学家预计，美联储官员本周将加快收缩购债步伐，并发出2022年加息的信号，在1980年代以来最强通胀面前上演历史性的政策转变。</p>\n<p>超过一半的受访者预计，美联储周三结束两天政策会议后发布的季度预测将显示，18位官员的中值预测是明年加息两次。这与他们9月份的预测相比有变化。当时，决策者在2022年或2023年首次加息的预测上平分秋色。“这将是点阵图历史上最大的鹰派转变，”Macropolicy Perspectives高级经济学家Laura Rosner-Warburton表示。美联储自2012年开始发布利率预测的点阵图。美联储主席杰罗姆·鲍威尔在11月30日对议员们表示，考虑加快减码进程，比原计划(2022年中)提前几个月结束可能是合适的。</p>\n<p>2、纽约联储调查显示：消费者对未来一年的通胀预期升至6%的新高</p>\n<p>纽约联邦储备银行最新消费者调查显示，美国消费者对未来一年的通胀预期升至6%的新高。调查还显示，三年通胀预期自6月以来首次下降，达到4%，主要是受到无大学学历受访者的预期推动。然而，无论是短期还是长期，通胀的不确定性水平都在上升，并且都达到了历史新高。</p>\n<p>3、牛津大学：omicron毒株能削弱两针<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>或<a href=\"https://laohu8.com/S/AZN\">阿斯利康</a>疫苗的保护力</p>\n<p>研究人员发现，正如人们所担忧的一样，omicron变异株削弱了辉瑞和阿斯利康两剂新冠疫苗所能提供的保护力，增加了接种者感染风险。牛津大学研究人员周一在一份报告中表示，在对接种辉瑞或阿斯利康疫苗的人采集的血液样本中，经检测新毒株omicron令中和抗体大幅减少，尤其是和德尔塔毒株相比，降幅很明显。</p>\n<p>4、约翰逊证实：英国已出现奥密克戎死亡病例 另有10人住院治疗</p>\n<p>英国首相鲍里斯·约翰逊周一(12月13日)证实，英国至少有一名感染新冠病毒奥密克戎毒株的患者死亡。</p>\n<p>约翰逊在访问伦敦帕丁顿附近的一家疫苗接种诊所时对记者说：“有几位奥密克戎感染者正在住院治疗。不幸的是，至少有一名患者被证实死于奥密克戎。”</p>\n<p>5、美国累计新冠肺炎确诊病例超5000万例</p>\n<p>当地时间13日，根据美国约翰斯·霍普金斯大学数据，截至美东时间当天14时22分(北京时间12月14日凌晨3时22分)，美国累计确诊新冠肺炎病例超5000万例，达50009507例；累计死亡病例达797916例。</p>\n<p>6、七国集团财长承诺解决供应链问题并避免未来重演</p>\n<p>七国集团财长承诺加强合作，以解决造成商品短缺和通胀飙升的全球供应链问题。由于运输问题导致供应中断，零部件制成品短缺以及疫情造成能源价格上涨，全球消费者价格都在飙升。美国通胀率已触及1982年以来的最高水平，欧元区通胀率达到了创纪录的4.9%。</p>\n<p>7、欧佩克月报：上调明年一季度全球原油需求预期 奥密克戎影响有限</p>\n<p>欧佩克周一表示，奥密克戎变体对全球原油市场的影响将是有限的，各国政府和企业现在已经适应且能够更好地应对新冠疫情。此外，欧佩克大幅上调了明年第一季度的原油需求预期。在其备受关注的最新月报中，欧佩克将2022年第一季度全球原油需求预期上调111万桶/日，至9913万桶/日； 将2022年全球需求预期上调20万桶/日，至2880万桶/日。</p>\n<p>8、加拿大央行重申2%通胀目标 将把就业最大化纳入使命范围</p>\n<p>加拿大央行将在未来五年维持2%的通胀目标，但允许小幅超过目标以支持可持续的就业最大化。在周一与加拿大政府联合发布的声明中，加拿大央行增加了一项新要求，即必要情况下，官员将使用1%-3%的控制区间来“继续”支持就业水平，但同时强调以通胀目标为首要。</p>\n<p>市场观点</p>\n<p>1、<a href=\"https://laohu8.com/NW/2191735989\" target=\"_blank\">美股瑟瑟发抖：经济学家普遍预期本周美联储将发布“最鹰点阵图”</a></p>\n<p>根据美国当地媒体周一发布的经济学家调查，眼下市场普遍预期美联储官员们本周将明确给出2022年加息的信号，同时加快缩减债券购买规模的速度。</p>\n<p>这项调查在今年12月3日至8日期间进行，值得一提的是，参与调查的49名经济学家中有超过半数认为，18位FOMC委员的中位点阵图预期将达到明年两次加息，这也与九月FOMC经济前瞻形成鲜明反差，当时18名委员中预测2022和2023年开始加息的各占一半。</p>\n<p>2、小摩预计美失业率明年将降至3%左右 奥密克戎是就业市场主要风险</p>\n<p><a href=\"https://laohu8.com/S/JPM\">摩根大通</a>首席美国经济学家Michael Feroli认为，2022年美国失业率将下降。“我认为到2022年底可以看到失业率在3%左右，”Feroli称。“过去五个月的失业率下降幅度令人深刻印象。我们预计下降速度会放缓，但很快就会降至4%以下。”在Feroli看来，随着雇主寻找人才以推动企业从疫情中复苏，就业市场可能会以良好的势头进入2022年。</p>\n<p>公司新闻</p>\n<p>1、<a href=\"https://laohu8.com/NW/2191988721\" target=\"_blank\">特斯拉CEO埃隆·马斯克当选时代杂志2021年度风云人物</a></p>\n<p>特斯拉CEO埃隆·马斯克(Elon Musk)今日被美国《时代》杂志评为“2021年度风云人物”。</p>\n<p>《时代》杂志称，作为世界上最富有的人，他没有房子，最近一直在抛售财产。他将卫星送入轨道，并利用<a href=\"https://laohu8.com/S/000591\">太阳能</a>服务千家万户。他驾驶着一辆自己制造的汽车，不需要汽油，也几乎不需要司机。他的手指一挥，股市就会暴涨或暴跌。他的每一句话都被一大群粉丝挂在嘴边。当他把业务推向全球时，还梦想着移民火星。</p>\n<p>2、<a href=\"https://laohu8.com/NW/2191828979\" target=\"_blank\">苹果周一收盘跌超2% 创11月26日以来最大单日跌幅</a></p>\n<p>苹果公司股价周一收盘大跌，未能跨越成为全球首家市值达到3万亿美元公司的里程碑。截至周一收盘，苹果公司股价下跌2.07%，报175.74美元，创11月26日以来最大单日跌幅，市值2.88万亿美元。该公司股价周一盘中最高达到182.13美元，市值最高达到2.987万亿美元。苹果公司市值要超越3万亿美元大关，股价需要达到182.86美元。</p>\n<p>3、<a href=\"https://laohu8.com/NW/2191881989\" target=\"_blank\">辉瑞溢价100%收购阿里那制药 交易总价值接近67亿美元</a></p>\n<p>当地时间周一，全球医药龙头辉瑞发布公告，将以高额溢价收购创新药开发公司阿里那(Arena)制药，后者在免疫炎症领域拥有多款在研产品。</p>\n<p>根据公告，辉瑞将以每股100美元的价格展开纯现金收购，这一价格较阿里那制药上周五收盘价49.94美元溢价达100%。受此消息影响，截至发稿阿里那股价上涨接近85%至92美元。在新冠疫苗和口服药领域取得科研和商业的双重成功后，财大气粗的辉瑞在公告中表示，这笔交易对阿里那制药的股权估值为67亿美元，公司手头的现金就足以支付。这项交易预期在2022年上半年完成。</p>\n<p>4、<a href=\"https://laohu8.com/NW/2191989094\" target=\"_blank\">哈雷电动摩托车部门拟以SPAC上市谋转型 估值17.7亿美元</a></p>\n<p>美东时间时间12月13日周一，<a href=\"https://laohu8.com/S/HOG\">哈雷戴维森</a>Harley Davidson公司表示，其电动摩托车部门LiveWire将通以SPAC Special Purpose Acquisition Corporation合并的方式上市，预计合并后的公司估值为17.7亿美元。</p>\n<p>5、<a href=\"https://laohu8.com/NW/2191098483\" target=\"_blank\">英特尔寻求扩大芯片产能 计划投资71亿美元在马来西亚设新厂</a></p>\n<p>据马来西亚政府机构周一(12月13日)称，芯片制造商英特尔公司(Intel)计划在马来西亚投资300亿林吉特(合71亿美元)建立最先进的半导体生产设施，扩大其生产能力。与此同时，美国政府正在积极推动全球各大半导体企业在美设厂，欲将芯片供应链留在美国国内。</p>\n<p>7、<a href=\"https://laohu8.com/NW/2191763986\" target=\"_blank\">瑞银集团协助客户逃税罪名成立 被罚约18亿欧元</a></p>\n<p>法国巴黎一家上诉法院判决瑞银(UBS.N)协助法国客户逃税的罪名成立，但将处罚金额从45亿欧元降至约18亿欧元。该法院表示，瑞银集团在2004年至2012年期间系统地帮助法国客户逃税，引诱他们将钱藏在瑞士。该案最初于2019年宣判，瑞银集团被罚款37亿欧元，外加8亿欧元的损害赔偿及利息。之后，瑞银集团对这一判决提出上诉。</p>\n<p>8、<a href=\"https://laohu8.com/NW/2191917607\" target=\"_blank\">瑞幸咖啡召开股东大会 防止前造假管理层获得股权</a></p>\n<p>12月13日，瑞幸咖啡发布公告称，瑞幸咖啡股东大会已于2021年12月11日召开。会议上通过了提交股东批准的拟议决议，以及公司第五次修订及重述的组织章程大纲及细则。这些拟议措施是为限制前造假管理层获得公司股权的能力，以此限制他们以直接或间接的方式影响公司，从而保护公司的长期生存能力。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/b23574aac95526c9e5c62ebc8dd25130","relate_stocks":{},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168636209","content_text":"摘要：①联储会议前美股收跌，道指下跌0.89%；②热门中概股收盘大多走低，瑞幸粉单跌近8%；③加速减码+预告加息，美联储可能上演历史罕见的鹰派转变；④英国出现首例奥密克戎死亡病例。\n\n海外市场\n1、联储会议前美股收跌 道指下跌320点\n周一(12月13日)，美股收盘走低，嘉年华公司和几家航空公司的股价暴跌，原因是在本周晚些时候美联储召开会议之前投资者对奥密克戎变种忧心忡忡。\n标准普尔500指数收盘下跌0.91%，较盘中高点下跌1.6%左右。受波音公司股价下跌3.7%的拖累，道琼斯指数下跌道指跌320.04点或0.89%。以科技股为主的纳斯达克综合指数下跌1.39%。\n2、热门中概股周一收盘大多走低 瑞幸粉单跌近8%\n热门中概股周一收盘大多走低，瑞幸粉单跌近8%，消息面，瑞幸咖啡召开股东大会，防止前造假管理层获得股权。\n热门中概股大多下跌。人人网ADR跌超17%，贝壳跌约15%，网易有道跌超14%，瑞幸咖啡跌近8%，哔哩哔哩跌超6%，腾讯音乐、新东方、斗鱼、爱奇艺跌超4%，拼多多、百度、小鹏汽车、理想汽车、中国恒大粉单跌超3%，阿里巴巴、京东、虎牙跌超2%，蔚来汽车跌超1%，腾讯ADR跌近0.8%，而叮咚买菜收涨超18%，第九城市近10%，掌门教育涨超4%，图森未来涨超1%。\n3、本周多国央行会议在即 欧股再次下滑\n欧洲股市周一(12月13日)下滑，泛欧斯托克600指数收盘跌幅0.5%，大多数板块都在下跌。投资者对奥密克戎病毒变体的发展做出反应，并等待本周主要央行的货币政策决定。这将是货币政策的重要一周，美国联邦储备委员会、日本央行、英国央行和欧洲央行都将在本周举行会议并作出货币政策决定。\n泛欧斯托克600指数收盘下跌2.03点，跌幅0.54%，报473.53点；德国DAX30指数收盘下跌2.91点，跌幅0.02%，报15620.40点。\n4、Omicron再次引发需求担忧 油价下跌\n交易商权衡Omicron变体的风险，而欧佩克上调了对全球原油需求的预测。周一(12月13日)，油价下跌。\n截至收盘，美国WTI原油期货下跌37美分，跌幅0.52%，报71.30美元/桶；布伦特期货下跌66美分，跌幅0.88%，报74.49美元/桶。\n5、年终大考在即黄金顽强走高 金价或很快突破1800美元大关\n周一(12月13日)，金价小幅走高，因投资者在本周关键的央行会议前增持仓位，美联储可能会发出信号，表明其可能会以什么速度退出大流行时期的经济支持措施。\n美市尾盘，现货黄金收报1786.48美元/盎司，上涨3.79美元或0.21%，日内最高触及1790.99美元高点，最低触及1781.37美元。上周，现货黄金收跌0.52美元或0.03%。\n国际宏观\n1、加速减码+预告加息 美联储可能上演历史罕见的鹰派转变\n经济学家预计，美联储官员本周将加快收缩购债步伐，并发出2022年加息的信号，在1980年代以来最强通胀面前上演历史性的政策转变。\n超过一半的受访者预计，美联储周三结束两天政策会议后发布的季度预测将显示，18位官员的中值预测是明年加息两次。这与他们9月份的预测相比有变化。当时，决策者在2022年或2023年首次加息的预测上平分秋色。“这将是点阵图历史上最大的鹰派转变，”Macropolicy Perspectives高级经济学家Laura Rosner-Warburton表示。美联储自2012年开始发布利率预测的点阵图。美联储主席杰罗姆·鲍威尔在11月30日对议员们表示，考虑加快减码进程，比原计划(2022年中)提前几个月结束可能是合适的。\n2、纽约联储调查显示：消费者对未来一年的通胀预期升至6%的新高\n纽约联邦储备银行最新消费者调查显示，美国消费者对未来一年的通胀预期升至6%的新高。调查还显示，三年通胀预期自6月以来首次下降，达到4%，主要是受到无大学学历受访者的预期推动。然而，无论是短期还是长期，通胀的不确定性水平都在上升，并且都达到了历史新高。\n3、牛津大学：omicron毒株能削弱两针辉瑞或阿斯利康疫苗的保护力\n研究人员发现，正如人们所担忧的一样，omicron变异株削弱了辉瑞和阿斯利康两剂新冠疫苗所能提供的保护力，增加了接种者感染风险。牛津大学研究人员周一在一份报告中表示，在对接种辉瑞或阿斯利康疫苗的人采集的血液样本中，经检测新毒株omicron令中和抗体大幅减少，尤其是和德尔塔毒株相比，降幅很明显。\n4、约翰逊证实：英国已出现奥密克戎死亡病例 另有10人住院治疗\n英国首相鲍里斯·约翰逊周一(12月13日)证实，英国至少有一名感染新冠病毒奥密克戎毒株的患者死亡。\n约翰逊在访问伦敦帕丁顿附近的一家疫苗接种诊所时对记者说：“有几位奥密克戎感染者正在住院治疗。不幸的是，至少有一名患者被证实死于奥密克戎。”\n5、美国累计新冠肺炎确诊病例超5000万例\n当地时间13日，根据美国约翰斯·霍普金斯大学数据，截至美东时间当天14时22分(北京时间12月14日凌晨3时22分)，美国累计确诊新冠肺炎病例超5000万例，达50009507例；累计死亡病例达797916例。\n6、七国集团财长承诺解决供应链问题并避免未来重演\n七国集团财长承诺加强合作，以解决造成商品短缺和通胀飙升的全球供应链问题。由于运输问题导致供应中断，零部件制成品短缺以及疫情造成能源价格上涨，全球消费者价格都在飙升。美国通胀率已触及1982年以来的最高水平，欧元区通胀率达到了创纪录的4.9%。\n7、欧佩克月报：上调明年一季度全球原油需求预期 奥密克戎影响有限\n欧佩克周一表示，奥密克戎变体对全球原油市场的影响将是有限的，各国政府和企业现在已经适应且能够更好地应对新冠疫情。此外，欧佩克大幅上调了明年第一季度的原油需求预期。在其备受关注的最新月报中，欧佩克将2022年第一季度全球原油需求预期上调111万桶/日，至9913万桶/日； 将2022年全球需求预期上调20万桶/日，至2880万桶/日。\n8、加拿大央行重申2%通胀目标 将把就业最大化纳入使命范围\n加拿大央行将在未来五年维持2%的通胀目标，但允许小幅超过目标以支持可持续的就业最大化。在周一与加拿大政府联合发布的声明中，加拿大央行增加了一项新要求，即必要情况下，官员将使用1%-3%的控制区间来“继续”支持就业水平，但同时强调以通胀目标为首要。\n市场观点\n1、美股瑟瑟发抖：经济学家普遍预期本周美联储将发布“最鹰点阵图”\n根据美国当地媒体周一发布的经济学家调查，眼下市场普遍预期美联储官员们本周将明确给出2022年加息的信号，同时加快缩减债券购买规模的速度。\n这项调查在今年12月3日至8日期间进行，值得一提的是，参与调查的49名经济学家中有超过半数认为，18位FOMC委员的中位点阵图预期将达到明年两次加息，这也与九月FOMC经济前瞻形成鲜明反差，当时18名委员中预测2022和2023年开始加息的各占一半。\n2、小摩预计美失业率明年将降至3%左右 奥密克戎是就业市场主要风险\n摩根大通首席美国经济学家Michael Feroli认为，2022年美国失业率将下降。“我认为到2022年底可以看到失业率在3%左右，”Feroli称。“过去五个月的失业率下降幅度令人深刻印象。我们预计下降速度会放缓，但很快就会降至4%以下。”在Feroli看来，随着雇主寻找人才以推动企业从疫情中复苏，就业市场可能会以良好的势头进入2022年。\n公司新闻\n1、特斯拉CEO埃隆·马斯克当选时代杂志2021年度风云人物\n特斯拉CEO埃隆·马斯克(Elon Musk)今日被美国《时代》杂志评为“2021年度风云人物”。\n《时代》杂志称，作为世界上最富有的人，他没有房子，最近一直在抛售财产。他将卫星送入轨道，并利用太阳能服务千家万户。他驾驶着一辆自己制造的汽车，不需要汽油，也几乎不需要司机。他的手指一挥，股市就会暴涨或暴跌。他的每一句话都被一大群粉丝挂在嘴边。当他把业务推向全球时，还梦想着移民火星。\n2、苹果周一收盘跌超2% 创11月26日以来最大单日跌幅\n苹果公司股价周一收盘大跌，未能跨越成为全球首家市值达到3万亿美元公司的里程碑。截至周一收盘，苹果公司股价下跌2.07%，报175.74美元，创11月26日以来最大单日跌幅，市值2.88万亿美元。该公司股价周一盘中最高达到182.13美元，市值最高达到2.987万亿美元。苹果公司市值要超越3万亿美元大关，股价需要达到182.86美元。\n3、辉瑞溢价100%收购阿里那制药 交易总价值接近67亿美元\n当地时间周一，全球医药龙头辉瑞发布公告，将以高额溢价收购创新药开发公司阿里那(Arena)制药，后者在免疫炎症领域拥有多款在研产品。\n根据公告，辉瑞将以每股100美元的价格展开纯现金收购，这一价格较阿里那制药上周五收盘价49.94美元溢价达100%。受此消息影响，截至发稿阿里那股价上涨接近85%至92美元。在新冠疫苗和口服药领域取得科研和商业的双重成功后，财大气粗的辉瑞在公告中表示，这笔交易对阿里那制药的股权估值为67亿美元，公司手头的现金就足以支付。这项交易预期在2022年上半年完成。\n4、哈雷电动摩托车部门拟以SPAC上市谋转型 估值17.7亿美元\n美东时间时间12月13日周一，哈雷戴维森Harley Davidson公司表示，其电动摩托车部门LiveWire将通以SPAC Special Purpose Acquisition Corporation合并的方式上市，预计合并后的公司估值为17.7亿美元。\n5、英特尔寻求扩大芯片产能 计划投资71亿美元在马来西亚设新厂\n据马来西亚政府机构周一(12月13日)称，芯片制造商英特尔公司(Intel)计划在马来西亚投资300亿林吉特(合71亿美元)建立最先进的半导体生产设施，扩大其生产能力。与此同时，美国政府正在积极推动全球各大半导体企业在美设厂，欲将芯片供应链留在美国国内。\n7、瑞银集团协助客户逃税罪名成立 被罚约18亿欧元\n法国巴黎一家上诉法院判决瑞银(UBS.N)协助法国客户逃税的罪名成立，但将处罚金额从45亿欧元降至约18亿欧元。该法院表示，瑞银集团在2004年至2012年期间系统地帮助法国客户逃税，引诱他们将钱藏在瑞士。该案最初于2019年宣判，瑞银集团被罚款37亿欧元，外加8亿欧元的损害赔偿及利息。之后，瑞银集团对这一判决提出上诉。\n8、瑞幸咖啡召开股东大会 防止前造假管理层获得股权\n12月13日，瑞幸咖啡发布公告称，瑞幸咖啡股东大会已于2021年12月11日召开。会议上通过了提交股东批准的拟议决议，以及公司第五次修订及重述的组织章程大纲及细则。这些拟议措施是为限制前造假管理层获得公司股权的能力，以此限制他们以直接或间接的方式影响公司，从而保护公司的长期生存能力。","news_type":1},"isVote":1,"tweetType":1,"viewCount":781,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604505963,"gmtCreate":1639408302840,"gmtModify":1639409297775,"author":{"id":"4092093145464560","authorId":"4092093145464560","name":"MrKeith","avatar":"https://static.tigerbbs.com/460dea2188efdfc37ad3bbaf86f6b649","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4092093145464560","authorIdStr":"4092093145464560"},"themes":[],"htmlText":"Interesting. I&nbsp;will research&nbsp;more on these retail giant… did they soar due to recent pandemic? Is ita long term growth? Shopify: they’re many onlinegiants emerging, including powerhouse Taobao, JD, etc. Will they hold their&nbsp;fort for long? Overall agood read. Thanks for sharing.&nbsp;","listText":"Interesting. I&nbsp;will research&nbsp;more on these retail giant… did they soar due to recent pandemic? Is ita long term growth? Shopify: they’re many onlinegiants emerging, including powerhouse Taobao, JD, etc. Will they hold their&nbsp;fort for long? Overall agood read. Thanks for sharing.&nbsp;","text":"Interesting. I will research more on these retail giant… did they soar due to recent pandemic? Is ita long term growth? Shopify: they’re many onlinegiants emerging, including powerhouse Taobao, JD, etc. Will they hold their fort for long? Overall agood read. Thanks for sharing.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604505963","repostId":"2191498346","repostType":4,"repost":{"id":"2191498346","kind":"highlight","pubTimestamp":1639404988,"share":"https://www.laohu8.com/m/news/2191498346?lang=&edition=full","pubTime":"2021-12-13 22:16","market":"us","language":"en","title":"3 High-Growth Stocks That Could Be Worth $1 Trillion in 10 Years – or Sooner","url":"https://stock-news.laohu8.com/highlight/detail?id=2191498346","media":"Motley Fool","summary":"These fast growers seem likely to keep growing -- a lot.","content":"<p>Not that many years ago, companies with market values topping $100 billion or $200 billion were quite impressive. But times have changed, and many large companies have grown far larger. In 2020, <b>Apple</b> became the first company to pass the $1 trillion mark. It now has plenty of company, with, for example, <b>Amazon.com</b>&nbsp;recently valued at $1.8 trillion and <b>Microsoft</b>&nbsp;carrying a $2.5 trillion price tag.</p>\n<p>Meanwhile, Apple itself recently sported a market capitalization of nearly $2.9 trillion. Here are three companies that seem poised to join the club within a decade, if not much sooner.</p>\n<h2><b>1. <a href=\"https://laohu8.com/S/CRM\">Salesforce</a>.com</b></h2>\n<p>You have likely heard of <b>Salesforce.com</b> (NYSE:CRM), as it has been around since&nbsp;1999 and has grown into a $260 billion enterprise. The company explains its business well in this&nbsp;nutshell: \" Salesforce is a customer relationship management [CRM] solution that brings companies and customers together. It's <a href=\"https://laohu8.com/S/AONE.U\">one</a> integrated CRM platform that gives all your departments — including marketing, sales, commerce, and service — a single, shared view of every customer.\" It's clearly doing well, as it has more than 150,000 businesses as customers.</p>\n<p>For Salesforce.com to become a trillion-dollar business, it has to roughly quadruple in value over a decade, which equates to an approximate annual growth rate of 15%. That's not a terribly tall order for the company, considering that its total revenue grew&nbsp;by 24% year over year in this fiscal year's first nine months, with the company projecting similar growth in its last quarter. Much of Salesforce's revenue is subscription-based, which is extra appealing, as that tends to be relatively reliable and automatic.</p>\n<p>Meanwhile, once customers start relying on the company's suite of software services, it can be hard for them to switch to another provider. This stickiness is a competitive advantage.</p>\n<h2><b>2. Costco</b></h2>\n<p><b>Costco</b> (NASDAQ:COST), the world's third-largest retailer, was recently valued near $235 billion. It, too, would need to roughly quadruple to hit that trillion-dollar value -- and doing so in a decade would require an average annual growth rate near 16%.</p>\n<p>Costco offers a lot to like for investors, as it does a much better than average job of serving its three main stakeholders: Customers, employees, and shareholders. It aims to cap price mark-ups at about 13% or 14%, it offers above-average pay and benefits, and it has grown in value by an annual average of more than 21% over the past decade.</p>\n<p>The company's revenue grew by more than 17% year over year in its fourth quarter, and its last fiscal year, with net income per share growing by more than 20% over both periods. As with any company, such robust growth rates are not guaranteed for the years ahead, and Costco's shares are not exactly cheap these days, but it still stands a decent chance of quadrupling within a decade -- and if not, perhaps soon thereafter.</p>\n<h2><b>3. Shopify</b></h2>\n<p><b>Shopify</b> (NASDAQ:SHOP) has likely given many shareholders nosebleeds from its rapid ascent since its 2015 initial public offering (IPO): Its shares have soared more&nbsp;than 8,800%, averaging an annual gain of about 98%. That pace of growth is <i>far </i>from likely to continue, but there's still ample room for the company to grow. Its recent market value was $190 billion, meaning that it will need to roughly quintuple in size to hit the trillion-dollar mark, averaging growth of about 18% annually over the coming decade.</p>\n<p>That may not be a stretch for the company that&nbsp;bills itself as \"The all-in-one commerce platform to start, run, and grow a business.\" Shopify President Harley Finkelstein has noted: \"It took 15 years for our merchants to get to $200 billion in cumulative GMV, and just 16 months to double that to $400 billion.\"</p>\n<p>Shopify offers tiers of differently priced services for companies of different sizes, ranging from&nbsp;$29 monthly for start-ups and entrepreneurs to more than $2,000 monthly for larger companies. It sees its total addressable market (TAM) for small businesses alone valued at $153 billion, defining it as \"Anyone who wants to make more money from their site than they pay for it.\" Already, Shopify is No. 2 in market share for U.S. Retail E-commerce Sales as of late 2020, behind only Amazon.com.</p>\n<p>These three companies have been growing rapidly and have plenty of room for further growth, though none are trading anywhere near bargain-basement prices. Buying into them now if you're a long-term investor will give you a decent chance of them hitting a trillion dollars in value within a decade, but for even better results and more margin of safety, you might consider adding these growth stocks to your watchlist while waiting for a pullback.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 High-Growth Stocks That Could Be Worth $1 Trillion in 10 Years – or Sooner</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 High-Growth Stocks That Could Be Worth $1 Trillion in 10 Years – or Sooner\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-13 22:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/13/3-high-growth-stocks-could-be-worth-1-trillion/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Not that many years ago, companies with market values topping $100 billion or $200 billion were quite impressive. But times have changed, and many large companies have grown far larger. In 2020, Apple...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/13/3-high-growth-stocks-could-be-worth-1-trillion/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4155":"大卖场与超市","BK4550":"红杉资本持仓","BK4527":"明星科技股","BK4528":"SaaS概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4534":"瑞士信贷持仓","BK4023":"应用软件","BK4504":"桥水持仓","BK4538":"云计算","BK4532":"文艺复兴科技持仓","BK4505":"高瓴资本持仓","IPO":"Renaissance IPO ETF","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","CRM":"赛富时","COST":"好市多","BK4561":"索罗斯持仓","BK4567":"ESG概念"},"source_url":"https://www.fool.com/investing/2021/12/13/3-high-growth-stocks-could-be-worth-1-trillion/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2191498346","content_text":"Not that many years ago, companies with market values topping $100 billion or $200 billion were quite impressive. But times have changed, and many large companies have grown far larger. In 2020, Apple became the first company to pass the $1 trillion mark. It now has plenty of company, with, for example, Amazon.com recently valued at $1.8 trillion and Microsoft carrying a $2.5 trillion price tag.\nMeanwhile, Apple itself recently sported a market capitalization of nearly $2.9 trillion. Here are three companies that seem poised to join the club within a decade, if not much sooner.\n1. Salesforce.com\nYou have likely heard of Salesforce.com (NYSE:CRM), as it has been around since 1999 and has grown into a $260 billion enterprise. The company explains its business well in this nutshell: \" Salesforce is a customer relationship management [CRM] solution that brings companies and customers together. It's one integrated CRM platform that gives all your departments — including marketing, sales, commerce, and service — a single, shared view of every customer.\" It's clearly doing well, as it has more than 150,000 businesses as customers.\nFor Salesforce.com to become a trillion-dollar business, it has to roughly quadruple in value over a decade, which equates to an approximate annual growth rate of 15%. That's not a terribly tall order for the company, considering that its total revenue grew by 24% year over year in this fiscal year's first nine months, with the company projecting similar growth in its last quarter. Much of Salesforce's revenue is subscription-based, which is extra appealing, as that tends to be relatively reliable and automatic.\nMeanwhile, once customers start relying on the company's suite of software services, it can be hard for them to switch to another provider. This stickiness is a competitive advantage.\n2. Costco\nCostco (NASDAQ:COST), the world's third-largest retailer, was recently valued near $235 billion. It, too, would need to roughly quadruple to hit that trillion-dollar value -- and doing so in a decade would require an average annual growth rate near 16%.\nCostco offers a lot to like for investors, as it does a much better than average job of serving its three main stakeholders: Customers, employees, and shareholders. It aims to cap price mark-ups at about 13% or 14%, it offers above-average pay and benefits, and it has grown in value by an annual average of more than 21% over the past decade.\nThe company's revenue grew by more than 17% year over year in its fourth quarter, and its last fiscal year, with net income per share growing by more than 20% over both periods. As with any company, such robust growth rates are not guaranteed for the years ahead, and Costco's shares are not exactly cheap these days, but it still stands a decent chance of quadrupling within a decade -- and if not, perhaps soon thereafter.\n3. Shopify\nShopify (NASDAQ:SHOP) has likely given many shareholders nosebleeds from its rapid ascent since its 2015 initial public offering (IPO): Its shares have soared more than 8,800%, averaging an annual gain of about 98%. That pace of growth is far from likely to continue, but there's still ample room for the company to grow. Its recent market value was $190 billion, meaning that it will need to roughly quintuple in size to hit the trillion-dollar mark, averaging growth of about 18% annually over the coming decade.\nThat may not be a stretch for the company that bills itself as \"The all-in-one commerce platform to start, run, and grow a business.\" Shopify President Harley Finkelstein has noted: \"It took 15 years for our merchants to get to $200 billion in cumulative GMV, and just 16 months to double that to $400 billion.\"\nShopify offers tiers of differently priced services for companies of different sizes, ranging from $29 monthly for start-ups and entrepreneurs to more than $2,000 monthly for larger companies. It sees its total addressable market (TAM) for small businesses alone valued at $153 billion, defining it as \"Anyone who wants to make more money from their site than they pay for it.\" Already, Shopify is No. 2 in market share for U.S. Retail E-commerce Sales as of late 2020, behind only Amazon.com.\nThese three companies have been growing rapidly and have plenty of room for further growth, though none are trading anywhere near bargain-basement prices. Buying into them now if you're a long-term investor will give you a decent chance of them hitting a trillion dollars in value within a decade, but for even better results and more margin of safety, you might consider adding these growth stocks to your watchlist while waiting for a pullback.","news_type":1},"isVote":1,"tweetType":1,"viewCount":742,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605221230,"gmtCreate":1639183005832,"gmtModify":1639183005832,"author":{"id":"4092093145464560","authorId":"4092093145464560","name":"MrKeith","avatar":"https://static.tigerbbs.com/460dea2188efdfc37ad3bbaf86f6b649","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4092093145464560","authorIdStr":"4092093145464560"},"themes":[],"htmlText":"Merck would be a better option comparing to Amgen. They diversified their products.&nbsp;","listText":"Merck would be a better option comparing to Amgen. They diversified their products.&nbsp;","text":"Merck would be a better option comparing to Amgen. They diversified their products.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/605221230","repostId":"1122303970","repostType":4,"repost":{"id":"1122303970","kind":"news","pubTimestamp":1639135689,"share":"https://www.laohu8.com/m/news/1122303970?lang=&edition=full","pubTime":"2021-12-10 19:28","market":"us","language":"en","title":"Is It Time to Buy the Dow's 3 Worst Performing Stocks This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=1122303970","media":"Motley Fool","summary":"Take a look to see if these dogs of the Dow are worth buying.","content":"<p>The&nbsp;<b>Dow Jones Industrial Average</b>&nbsp;is an index made up of 30 of the largest and most influential companies on U.S. stock exchanges. The index has historically returned around 7.5% each year, so being up over 15% makes 2021 a year to celebrate.</p>\n<p>Not every stock in the Dow Jones has performed well. The three stocks we'll discuss are all down and have been since the beginning of 2021, despite the index being up so much. We'll look at each one to determine whether they represent an opportunity or are down for a good reason.</p>\n<p><b>1. Amgen</b></p>\n<p>Biotech company&nbsp;<b>Amgen</b>&nbsp;has been down about 7% since the beginning of 2021. The company develops and sells drugs aimed at inflammation, cancer, bone health, heart disease, and more.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/115c1a57215446a5a83d447ffbb995ca\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<p>When a company invents a successful drug, its formula is patented, protecting it from direct competition for many years. Medications can cost millions of dollars to research and develop but can fail when tested in trials. A successful drug sometimes referred to as a blockbuster, can bring in billions in revenue over the length of its patent.</p>\n<p>Investors can get a feel for the trajectory of a drug company by following when its key products lose their patent protection. Once this happens, generic competitors flood the market at lower prices, significantly reducing the original drug's sales.</p>\n<p>Many of Amgen's primary products could lose sales when their patents expire:</p>\n<ul>\n <li>Enbrel (19% of revenue) expires in the U.S. in 2029.</li>\n <li>Prolia (12% of revenue) expires in the U.S. in 2025.</li>\n <li>Otezla (9% of revenue) expires in the U.S. in 2028.</li>\n <li>Xgeva (8% of revenue) expires in the U.S. in 2025.</li>\n</ul>\n<p>The United States has a more-complicated patent system, where drug companies can extend their patents by making minor changes to them. This, combined with the high drug prices charged in the U.S. market, is why domestic sales account for 68% of Amgen's global revenue. As these patents expire over the next decade, the company will&nbsp;need its pipeline to deliver&nbsp;successful products to replace this lost revenue.</p>\n<p>The stock currently trades at a&nbsp;price-to-earnings ratio&nbsp;(P/E) of 12 using analyst estimates for 2021&nbsp;earnings per share&nbsp;(EPS), far less than its historical average of 17. Analysts are calling for growth of 8% per year over the next three to five years, and pharmaceutical companies face political pressure in the United States due to drug prices. These risks probably justify a discounted valuation, and that's just what the stock offers at these levels.</p>\n<p><b>Verdict: thumbs-up</b></p>\n<p><b>2. Merck</b></p>\n<p>A rival to Amgen,<b>Merck</b>&nbsp;develops drugs for cancer, immunology, and virology, as well as vaccine products, along with a separate business unit that develops drugs for veterinary use. The stock has maintained its 11% decline since the beginning of the year.</p>\n<p>Merck doesn't have a patent cliff that's quite as imminent as Amgen's. Its Januvia/Janumet accounts for about 10% of sales, and its patent expires in 2022, but the patents for the rest of Merck's significant drugs like Keytruda (34% of revenue) and Gardasil (15% of revenue) don't expire until 2028.</p>\n<p>The company also released positive results from its clinical trials on molnupiravir, a pill that, when taken at the early stages of COVID-19 infection, can reduce the risk of serious illness by 30%. Merck has already agreed to sell more than $2.2 billion in treatments, so as the omicron variant continues to spread, it could give a spark to Merck's business. Rival&nbsp;<b>Pfizer</b>&nbsp;is also bringing a similar pill to market, but there could be&nbsp;enough demand for both to succeedhere.</p>\n<p>The stock is trading at a P/E of 11, a significant discount to its historical P/E of 27. Analysts are calling for modest growth of 6% per year over the next three to five years, but that might be conservative due to COVID treatments. Investors might not be factoring in the potential business from the COVID pill, and the valuation markdown could provide a margin of safety.</p>\n<p><b>Verdict: thumbs-up</b></p>\n<p><b>3. Verizon Communications</b></p>\n<p>Down 14% year to date, telecom company&nbsp;<b>Verizon Communications</b>&nbsp;is among a select few companies that control the wireless networks in the United States. The infrastructure that supports our nationwide phone network costs billions of dollars and took years to build out, so there is a minor threat from outside competition, even with fierce competitors like&nbsp;<b>AT&amp;T</b>&nbsp;and&nbsp;<b>T-Mobile</b>.</p>\n<p>The stock trades at a P/E of just over 9 based on 2021 EPS estimates. This is a bargain valuation if we look at its historical average, 14. While many would assume that 5G technology would unlock a lot of growth, Verizon has historically been a slow-growing business even with the emergence of 3G and 4G networks over time.</p>\n<p>Analysts estimate the company's three-to-five-year EPS growth at around 3% annually. Defensive investors who want a solid dividend can benefit here: It pays a dividend that yields 5% and needs just half of its profits to afford that payment. Investors focused on total returns probably won't get excited about Verizon, even at this reduced valuation.</p>\n<p><b>Verdict: thumbs-down</b></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time to Buy the Dow's 3 Worst Performing Stocks This Year?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time to Buy the Dow's 3 Worst Performing Stocks This Year?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-10 19:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/10/is-it-time-to-buy-the-dow-jones-3-worst-performing/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Dow Jones Industrial Average is an index made up of 30 of the largest and most influential companies on U.S. stock exchanges. The index has historically returned around 7.5% each year, so being up...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/10/is-it-time-to-buy-the-dow-jones-3-worst-performing/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMGN":"安进","MRK":"默沙东","VZ":"威瑞森"},"source_url":"https://www.fool.com/investing/2021/12/10/is-it-time-to-buy-the-dow-jones-3-worst-performing/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122303970","content_text":"The Dow Jones Industrial Average is an index made up of 30 of the largest and most influential companies on U.S. stock exchanges. The index has historically returned around 7.5% each year, so being up over 15% makes 2021 a year to celebrate.\nNot every stock in the Dow Jones has performed well. The three stocks we'll discuss are all down and have been since the beginning of 2021, despite the index being up so much. We'll look at each one to determine whether they represent an opportunity or are down for a good reason.\n1. Amgen\nBiotech company Amgen has been down about 7% since the beginning of 2021. The company develops and sells drugs aimed at inflammation, cancer, bone health, heart disease, and more.\nImage source: Getty Images.\nWhen a company invents a successful drug, its formula is patented, protecting it from direct competition for many years. Medications can cost millions of dollars to research and develop but can fail when tested in trials. A successful drug sometimes referred to as a blockbuster, can bring in billions in revenue over the length of its patent.\nInvestors can get a feel for the trajectory of a drug company by following when its key products lose their patent protection. Once this happens, generic competitors flood the market at lower prices, significantly reducing the original drug's sales.\nMany of Amgen's primary products could lose sales when their patents expire:\n\nEnbrel (19% of revenue) expires in the U.S. in 2029.\nProlia (12% of revenue) expires in the U.S. in 2025.\nOtezla (9% of revenue) expires in the U.S. in 2028.\nXgeva (8% of revenue) expires in the U.S. in 2025.\n\nThe United States has a more-complicated patent system, where drug companies can extend their patents by making minor changes to them. This, combined with the high drug prices charged in the U.S. market, is why domestic sales account for 68% of Amgen's global revenue. As these patents expire over the next decade, the company will need its pipeline to deliver successful products to replace this lost revenue.\nThe stock currently trades at a price-to-earnings ratio (P/E) of 12 using analyst estimates for 2021 earnings per share (EPS), far less than its historical average of 17. Analysts are calling for growth of 8% per year over the next three to five years, and pharmaceutical companies face political pressure in the United States due to drug prices. These risks probably justify a discounted valuation, and that's just what the stock offers at these levels.\nVerdict: thumbs-up\n2. Merck\nA rival to Amgen,Merck develops drugs for cancer, immunology, and virology, as well as vaccine products, along with a separate business unit that develops drugs for veterinary use. The stock has maintained its 11% decline since the beginning of the year.\nMerck doesn't have a patent cliff that's quite as imminent as Amgen's. Its Januvia/Janumet accounts for about 10% of sales, and its patent expires in 2022, but the patents for the rest of Merck's significant drugs like Keytruda (34% of revenue) and Gardasil (15% of revenue) don't expire until 2028.\nThe company also released positive results from its clinical trials on molnupiravir, a pill that, when taken at the early stages of COVID-19 infection, can reduce the risk of serious illness by 30%. Merck has already agreed to sell more than $2.2 billion in treatments, so as the omicron variant continues to spread, it could give a spark to Merck's business. Rival Pfizer is also bringing a similar pill to market, but there could be enough demand for both to succeedhere.\nThe stock is trading at a P/E of 11, a significant discount to its historical P/E of 27. Analysts are calling for modest growth of 6% per year over the next three to five years, but that might be conservative due to COVID treatments. Investors might not be factoring in the potential business from the COVID pill, and the valuation markdown could provide a margin of safety.\nVerdict: thumbs-up\n3. Verizon Communications\nDown 14% year to date, telecom company Verizon Communications is among a select few companies that control the wireless networks in the United States. The infrastructure that supports our nationwide phone network costs billions of dollars and took years to build out, so there is a minor threat from outside competition, even with fierce competitors like AT&T and T-Mobile.\nThe stock trades at a P/E of just over 9 based on 2021 EPS estimates. This is a bargain valuation if we look at its historical average, 14. While many would assume that 5G technology would unlock a lot of growth, Verizon has historically been a slow-growing business even with the emergence of 3G and 4G networks over time.\nAnalysts estimate the company's three-to-five-year EPS growth at around 3% annually. Defensive investors who want a solid dividend can benefit here: It pays a dividend that yields 5% and needs just half of its profits to afford that payment. Investors focused on total returns probably won't get excited about Verizon, even at this reduced valuation.\nVerdict: thumbs-down","news_type":1},"isVote":1,"tweetType":1,"viewCount":1112,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605062939,"gmtCreate":1639094376045,"gmtModify":1639094376045,"author":{"id":"4092093145464560","authorId":"4092093145464560","name":"MrKeith","avatar":"https://static.tigerbbs.com/460dea2188efdfc37ad3bbaf86f6b649","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4092093145464560","authorIdStr":"4092093145464560"},"themes":[],"htmlText":"Good news to buy?","listText":"Good news to buy?","text":"Good news to buy?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605062939","repostId":"1163135799","repostType":4,"isVote":1,"tweetType":1,"viewCount":684,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":605221230,"gmtCreate":1639183005832,"gmtModify":1639183005832,"author":{"id":"4092093145464560","authorId":"4092093145464560","name":"MrKeith","avatar":"https://static.tigerbbs.com/460dea2188efdfc37ad3bbaf86f6b649","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4092093145464560","authorIdStr":"4092093145464560"},"themes":[],"htmlText":"Merck would be a better option comparing to Amgen. They diversified their products.&nbsp;","listText":"Merck would be a better option comparing to Amgen. They diversified their products.&nbsp;","text":"Merck would be a better option comparing to Amgen. They diversified their products.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/605221230","repostId":"1122303970","repostType":4,"repost":{"id":"1122303970","kind":"news","pubTimestamp":1639135689,"share":"https://www.laohu8.com/m/news/1122303970?lang=&edition=full","pubTime":"2021-12-10 19:28","market":"us","language":"en","title":"Is It Time to Buy the Dow's 3 Worst Performing Stocks This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=1122303970","media":"Motley Fool","summary":"Take a look to see if these dogs of the Dow are worth buying.","content":"<p>The&nbsp;<b>Dow Jones Industrial Average</b>&nbsp;is an index made up of 30 of the largest and most influential companies on U.S. stock exchanges. The index has historically returned around 7.5% each year, so being up over 15% makes 2021 a year to celebrate.</p>\n<p>Not every stock in the Dow Jones has performed well. The three stocks we'll discuss are all down and have been since the beginning of 2021, despite the index being up so much. We'll look at each one to determine whether they represent an opportunity or are down for a good reason.</p>\n<p><b>1. Amgen</b></p>\n<p>Biotech company&nbsp;<b>Amgen</b>&nbsp;has been down about 7% since the beginning of 2021. The company develops and sells drugs aimed at inflammation, cancer, bone health, heart disease, and more.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/115c1a57215446a5a83d447ffbb995ca\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<p>When a company invents a successful drug, its formula is patented, protecting it from direct competition for many years. Medications can cost millions of dollars to research and develop but can fail when tested in trials. A successful drug sometimes referred to as a blockbuster, can bring in billions in revenue over the length of its patent.</p>\n<p>Investors can get a feel for the trajectory of a drug company by following when its key products lose their patent protection. Once this happens, generic competitors flood the market at lower prices, significantly reducing the original drug's sales.</p>\n<p>Many of Amgen's primary products could lose sales when their patents expire:</p>\n<ul>\n <li>Enbrel (19% of revenue) expires in the U.S. in 2029.</li>\n <li>Prolia (12% of revenue) expires in the U.S. in 2025.</li>\n <li>Otezla (9% of revenue) expires in the U.S. in 2028.</li>\n <li>Xgeva (8% of revenue) expires in the U.S. in 2025.</li>\n</ul>\n<p>The United States has a more-complicated patent system, where drug companies can extend their patents by making minor changes to them. This, combined with the high drug prices charged in the U.S. market, is why domestic sales account for 68% of Amgen's global revenue. As these patents expire over the next decade, the company will&nbsp;need its pipeline to deliver&nbsp;successful products to replace this lost revenue.</p>\n<p>The stock currently trades at a&nbsp;price-to-earnings ratio&nbsp;(P/E) of 12 using analyst estimates for 2021&nbsp;earnings per share&nbsp;(EPS), far less than its historical average of 17. Analysts are calling for growth of 8% per year over the next three to five years, and pharmaceutical companies face political pressure in the United States due to drug prices. These risks probably justify a discounted valuation, and that's just what the stock offers at these levels.</p>\n<p><b>Verdict: thumbs-up</b></p>\n<p><b>2. Merck</b></p>\n<p>A rival to Amgen,<b>Merck</b>&nbsp;develops drugs for cancer, immunology, and virology, as well as vaccine products, along with a separate business unit that develops drugs for veterinary use. The stock has maintained its 11% decline since the beginning of the year.</p>\n<p>Merck doesn't have a patent cliff that's quite as imminent as Amgen's. Its Januvia/Janumet accounts for about 10% of sales, and its patent expires in 2022, but the patents for the rest of Merck's significant drugs like Keytruda (34% of revenue) and Gardasil (15% of revenue) don't expire until 2028.</p>\n<p>The company also released positive results from its clinical trials on molnupiravir, a pill that, when taken at the early stages of COVID-19 infection, can reduce the risk of serious illness by 30%. Merck has already agreed to sell more than $2.2 billion in treatments, so as the omicron variant continues to spread, it could give a spark to Merck's business. Rival&nbsp;<b>Pfizer</b>&nbsp;is also bringing a similar pill to market, but there could be&nbsp;enough demand for both to succeedhere.</p>\n<p>The stock is trading at a P/E of 11, a significant discount to its historical P/E of 27. Analysts are calling for modest growth of 6% per year over the next three to five years, but that might be conservative due to COVID treatments. Investors might not be factoring in the potential business from the COVID pill, and the valuation markdown could provide a margin of safety.</p>\n<p><b>Verdict: thumbs-up</b></p>\n<p><b>3. Verizon Communications</b></p>\n<p>Down 14% year to date, telecom company&nbsp;<b>Verizon Communications</b>&nbsp;is among a select few companies that control the wireless networks in the United States. The infrastructure that supports our nationwide phone network costs billions of dollars and took years to build out, so there is a minor threat from outside competition, even with fierce competitors like&nbsp;<b>AT&amp;T</b>&nbsp;and&nbsp;<b>T-Mobile</b>.</p>\n<p>The stock trades at a P/E of just over 9 based on 2021 EPS estimates. This is a bargain valuation if we look at its historical average, 14. While many would assume that 5G technology would unlock a lot of growth, Verizon has historically been a slow-growing business even with the emergence of 3G and 4G networks over time.</p>\n<p>Analysts estimate the company's three-to-five-year EPS growth at around 3% annually. Defensive investors who want a solid dividend can benefit here: It pays a dividend that yields 5% and needs just half of its profits to afford that payment. Investors focused on total returns probably won't get excited about Verizon, even at this reduced valuation.</p>\n<p><b>Verdict: thumbs-down</b></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time to Buy the Dow's 3 Worst Performing Stocks This Year?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time to Buy the Dow's 3 Worst Performing Stocks This Year?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-10 19:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/10/is-it-time-to-buy-the-dow-jones-3-worst-performing/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Dow Jones Industrial Average is an index made up of 30 of the largest and most influential companies on U.S. stock exchanges. The index has historically returned around 7.5% each year, so being up...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/10/is-it-time-to-buy-the-dow-jones-3-worst-performing/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMGN":"安进","MRK":"默沙东","VZ":"威瑞森"},"source_url":"https://www.fool.com/investing/2021/12/10/is-it-time-to-buy-the-dow-jones-3-worst-performing/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122303970","content_text":"The Dow Jones Industrial Average is an index made up of 30 of the largest and most influential companies on U.S. stock exchanges. The index has historically returned around 7.5% each year, so being up over 15% makes 2021 a year to celebrate.\nNot every stock in the Dow Jones has performed well. The three stocks we'll discuss are all down and have been since the beginning of 2021, despite the index being up so much. We'll look at each one to determine whether they represent an opportunity or are down for a good reason.\n1. Amgen\nBiotech company Amgen has been down about 7% since the beginning of 2021. The company develops and sells drugs aimed at inflammation, cancer, bone health, heart disease, and more.\nImage source: Getty Images.\nWhen a company invents a successful drug, its formula is patented, protecting it from direct competition for many years. Medications can cost millions of dollars to research and develop but can fail when tested in trials. A successful drug sometimes referred to as a blockbuster, can bring in billions in revenue over the length of its patent.\nInvestors can get a feel for the trajectory of a drug company by following when its key products lose their patent protection. Once this happens, generic competitors flood the market at lower prices, significantly reducing the original drug's sales.\nMany of Amgen's primary products could lose sales when their patents expire:\n\nEnbrel (19% of revenue) expires in the U.S. in 2029.\nProlia (12% of revenue) expires in the U.S. in 2025.\nOtezla (9% of revenue) expires in the U.S. in 2028.\nXgeva (8% of revenue) expires in the U.S. in 2025.\n\nThe United States has a more-complicated patent system, where drug companies can extend their patents by making minor changes to them. This, combined with the high drug prices charged in the U.S. market, is why domestic sales account for 68% of Amgen's global revenue. As these patents expire over the next decade, the company will need its pipeline to deliver successful products to replace this lost revenue.\nThe stock currently trades at a price-to-earnings ratio (P/E) of 12 using analyst estimates for 2021 earnings per share (EPS), far less than its historical average of 17. Analysts are calling for growth of 8% per year over the next three to five years, and pharmaceutical companies face political pressure in the United States due to drug prices. These risks probably justify a discounted valuation, and that's just what the stock offers at these levels.\nVerdict: thumbs-up\n2. Merck\nA rival to Amgen,Merck develops drugs for cancer, immunology, and virology, as well as vaccine products, along with a separate business unit that develops drugs for veterinary use. The stock has maintained its 11% decline since the beginning of the year.\nMerck doesn't have a patent cliff that's quite as imminent as Amgen's. Its Januvia/Janumet accounts for about 10% of sales, and its patent expires in 2022, but the patents for the rest of Merck's significant drugs like Keytruda (34% of revenue) and Gardasil (15% of revenue) don't expire until 2028.\nThe company also released positive results from its clinical trials on molnupiravir, a pill that, when taken at the early stages of COVID-19 infection, can reduce the risk of serious illness by 30%. Merck has already agreed to sell more than $2.2 billion in treatments, so as the omicron variant continues to spread, it could give a spark to Merck's business. Rival Pfizer is also bringing a similar pill to market, but there could be enough demand for both to succeedhere.\nThe stock is trading at a P/E of 11, a significant discount to its historical P/E of 27. Analysts are calling for modest growth of 6% per year over the next three to five years, but that might be conservative due to COVID treatments. Investors might not be factoring in the potential business from the COVID pill, and the valuation markdown could provide a margin of safety.\nVerdict: thumbs-up\n3. Verizon Communications\nDown 14% year to date, telecom company Verizon Communications is among a select few companies that control the wireless networks in the United States. The infrastructure that supports our nationwide phone network costs billions of dollars and took years to build out, so there is a minor threat from outside competition, even with fierce competitors like AT&T and T-Mobile.\nThe stock trades at a P/E of just over 9 based on 2021 EPS estimates. This is a bargain valuation if we look at its historical average, 14. While many would assume that 5G technology would unlock a lot of growth, Verizon has historically been a slow-growing business even with the emergence of 3G and 4G networks over time.\nAnalysts estimate the company's three-to-five-year EPS growth at around 3% annually. Defensive investors who want a solid dividend can benefit here: It pays a dividend that yields 5% and needs just half of its profits to afford that payment. Investors focused on total returns probably won't get excited about Verizon, even at this reduced valuation.\nVerdict: thumbs-down","news_type":1},"isVote":1,"tweetType":1,"viewCount":1112,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604505963,"gmtCreate":1639408302840,"gmtModify":1639409297775,"author":{"id":"4092093145464560","authorId":"4092093145464560","name":"MrKeith","avatar":"https://static.tigerbbs.com/460dea2188efdfc37ad3bbaf86f6b649","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4092093145464560","authorIdStr":"4092093145464560"},"themes":[],"htmlText":"Interesting. I&nbsp;will research&nbsp;more on these retail giant… did they soar due to recent pandemic? Is ita long term growth? Shopify: they’re many onlinegiants emerging, including powerhouse Taobao, JD, etc. Will they hold their&nbsp;fort for long? Overall agood read. Thanks for sharing.&nbsp;","listText":"Interesting. I&nbsp;will research&nbsp;more on these retail giant… did they soar due to recent pandemic? Is ita long term growth? Shopify: they’re many onlinegiants emerging, including powerhouse Taobao, JD, etc. Will they hold their&nbsp;fort for long? Overall agood read. Thanks for sharing.&nbsp;","text":"Interesting. I will research more on these retail giant… did they soar due to recent pandemic? Is ita long term growth? Shopify: they’re many onlinegiants emerging, including powerhouse Taobao, JD, etc. Will they hold their fort for long? Overall agood read. Thanks for sharing.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604505963","repostId":"2191498346","repostType":4,"isVote":1,"tweetType":1,"viewCount":742,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690092052,"gmtCreate":1639611965754,"gmtModify":1639611965754,"author":{"id":"4092093145464560","authorId":"4092093145464560","name":"MrKeith","avatar":"https://static.tigerbbs.com/460dea2188efdfc37ad3bbaf86f6b649","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4092093145464560","authorIdStr":"4092093145464560"},"themes":[],"htmlText":"Bad news?","listText":"Bad news?","text":"Bad news?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/690092052","repostId":"2191499479","repostType":2,"repost":{"id":"2191499479","kind":"news","pubTimestamp":1639604040,"share":"https://www.laohu8.com/m/news/2191499479?lang=&edition=full","pubTime":"2021-12-16 05:34","market":"us","language":"zh","title":"外媒头条：美联储官宣加速Taper！暗示明年加息三次","url":"https://stock-news.laohu8.com/highlight/detail?id=2191499479","media":"市场资讯","summary":"　　美联储周三向市场提供了多项迹象，表明其自新冠疫情开始以来的超宽松政策即将结束，其举措甚至比市场预期的还要激进。　　美联储点阵图显示，所有委员均预计美联储将在2022年开始加息，具体为2022年和2023年分别加息三次。委员们对政策举措持鹰派态度，坚定地倾向于加息。在18名FOMC委员中，12名委员认为明年至少将加息3次，6名预计明年加息不到3次，没有任何委员看到明年利率保持当前近零水平。","content":"<p><b>全球财经媒体昨夜今晨共同关注的头条新闻主要有：</b></p>\n<blockquote>\n <b>1、美联储维持利率不变 宣布加速Taper 点阵图显示明年加息三次</b>\n</blockquote>\n<blockquote>\n <b>2、Omicron加速蔓延 英国Covid病例创下纪录高点</b>\n</blockquote>\n<blockquote>\n <b>3、美国11月零售销售增幅低于预期 表明高通胀正在抑制消费</b>\n</blockquote>\n<blockquote>\n <b>4、全球债务达到创纪录226万亿美元 IMF担心利率上升带来可持续性风险</b>\n</blockquote>\n<blockquote>\n <b>5、美国证券交易委员会计划收紧企业高管的股票出售规定</b>\n</blockquote>\n<blockquote>\n <b>6、美联储隔夜逆回购使用规模再创历史新高 达到1.62万亿美元</b>\n</blockquote>\n<p><img src=\"https://static.tigerbbs.com/50acb966ae0fa22fd804334cd3285156\" tg-width=\"550\" tg-height=\"305\" referrerpolicy=\"no-referrer\"></p>\n<p><b>美联储维持利率不变 宣布加速Taper 点阵图显示明年加息三次</b></p>\n<p>美联储周三向市场提供了多项迹象，表明其自新冠疫情开始以来的超宽松政策即将结束，其举措甚至比市场预期的还要激进。</p>\n<p>美国联邦公开市场委员会（FOMC）当地时间周三公布最新利率决议，将基准利率维持在0%-0.25%区间不变，将超额准备金利率（IOER）维持在0.15%不变，将隔夜逆回购利率维持在0.05%不变，符合市场的普遍预期。</p>\n<p>FOMC声明称，从明年1月起，将每月资产购买规模减少300亿美元，即月度美国国债购买规模降低200亿美元、抵押贷款支持证券（MBS）减少100亿美元，此前为每月减少150亿美元。声明称，委员会认为，可能每月都适合这样减少净购买资产，但如果经济前景发生变化，将准备调整购债速度。</p>\n<p>美联储点阵图显示，所有委员均预计美联储将在2022年开始加息，具体为2022年和2023年分别加息三次。委员们对政策举措持鹰派态度，坚定地倾向于加息。在18名FOMC委员中，12名委员认为明年至少将加息3次，6名预计明年加息不到3次，没有任何委员看到明年利率保持当前近零水平。</p>\n<p><img src=\"https://static.tigerbbs.com/18b297bd677c579650af4b7c8b9df6cd\" tg-width=\"480\" tg-height=\"360\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Omicron加速蔓延 英国Covid病例创下纪录高点</b></p>\n<p>英国周三报告了78610例新增新冠病例，为大流行病爆发以来新高，凸显出omicron变异毒株的高传播性。</p>\n<p>之前的纪录高点是在1月8日的68053例，当时英国正处于阿尔法变种引发疫情浪潮、英国进入封锁状态几天之后。</p>\n<p>科研顾问警告称，首相鲍里斯·约翰逊称之为“海啸般的”一波omicron感染浪潮将导致住院人数增加。</p>\n<p>目前尚不清楚疫苗对这种变异毒株有多大效力，不过早期研究表明，两剂疫苗加一剂加强针可以提供针对omicron毒株75%的保护。</p>\n<p>虽然英国的阳性检测结果正在加速增长，但死亡人数远低于大流行病早期的水平。科学家们希望即使在病例数上升的情况下，快速推进加强针的接种能够帮助将重症病例数保持在较低水平。</p>\n<p><img src=\"https://static.tigerbbs.com/78b40d4e4573d972aa08df28c761e4bf\" tg-width=\"550\" tg-height=\"367\" referrerpolicy=\"no-referrer\"></p>\n<p><b>美国11月零售销售增幅低于预期 表明高通胀正在抑制消费</b></p>\n<p>美国11月零售销售增幅低于预期，表明在通胀率达到数十年来最高的背景下，消费者正在抑制购物。</p>\n<p>美国商务部周三的数据显示，11月份的总体零售额增长0.3%，10月份的数据向上修正为增长1.8%。不包括汽油和汽车，11月销售额增长0.2%。上述数字没有经过通胀调整。</p>\n<p>媒体调查得出的预测中值显示，经济学家预计11月整体零售额环比增长0.8%。</p>\n<p>弱于预期的报告可能反映了假日销售前移的影响，因为许多知道供应链困难的美国人比平常更早进行假日购物。</p>\n<p><img src=\"https://static.tigerbbs.com/66939b0633e54bb821942a2020b57625\" tg-width=\"550\" tg-height=\"367\" referrerpolicy=\"no-referrer\"></p>\n<p><b>全球债务达到创纪录226万亿美元 IMF担心利率上升带来可持续性风险</b></p>\n<p>国际货币基金组织（IMF）称，全球债务去年飙升至创纪录的226万亿美元，随着利率上升，引发了对债务可持续性的担忧。</p>\n<p>IMF官员周三在一份报告中表示，快于预期的加息可能会给高负债国家带来压力，并迫使政府和企业削减债务和支出，损害经济增长。</p>\n<p>他们援引IMF最新的全球债务数据库称，2020年全球债务/GDP比率上升28个百分点，达到256%，是二战以来升幅最大的一年。</p>\n<p>随着利率上升，财政政策通常会调整，因为政府要拿更多钱还债，并削减支出以控制赤字。</p>\n<p>“如果全球利率上升速度快于预期且经济增长放缓，那么风险将被放大，”&nbsp;Vitor Gaspar牵头的IMF官员写道。“如果公共和私营部门被迫同时去杠杆，增长前景将受到影响。”</p>\n<p><img src=\"https://static.tigerbbs.com/9c8348539976fbadc99ebaa9f1763592\" tg-width=\"550\" tg-height=\"305\" referrerpolicy=\"no-referrer\"></p>\n<p><b>美国证券交易委员会计划收紧企业高管的股票出售规定</b></p>\n<p>长期以来，企业负责人一直被怀疑规避意在防止高层管理人员利用内线消息进行交易的规定。现在，美国证券交易委员会正想办法打击这类交易。</p>\n<p>监管机构正在处理一个争议的问题：什么时候可以允许可能接触到重要非公开消息的公司内部人士出售股票？目前，企业高层主管可以只在抛售股票的前几天拟定出售计划，参议员Elizabeth Warren和其他立法者指出，这使得他们能在发布足以影响股价的公司公告前提前动作。</p>\n<p>美国证券交易委员会官员称，作为回应，该委员会准备提出新规则，迫使公司内部人士在安排出售至真正卖出股票之间等待大约四个月的时间。</p>\n<p>该机构将在周三的会议上就提出新限制措施进行表决。现行法规于20年前制定，旨在帮助高层管理人员出售股票并避免日后被指控进行内线交易。但最近的学术研究显示，股票销售计划充斥着可疑的特定时点交易。证券交易委员会主席Gary Gensler于6月表示，这些与企业相关的政策“导致我们的内线交易规范出现了真正的裂缝”。</p>\n<p>“这项提案解决了我们发现的一些漏洞，”Gensler在计划投票前接受采访时说。“这将有助于增强对资本市场的信任。”</p>\n<p><img src=\"https://static.tigerbbs.com/04efb4451f7dd35befcdc79a3423aa11\" tg-width=\"550\" tg-height=\"367\" referrerpolicy=\"no-referrer\"></p>\n<p><b>美联储隔夜逆回购使用规模再创历史新高 达到1.62万亿美元</b></p>\n<p>投资者在美联储一个重要政策工具存放的资金创下历史新高。</p>\n<p>八十五名对手方周三利用隔夜逆回购协议存入美联储的资金达到1.62万亿美元，打破了第三季度最后一个交易日创下的1.605万亿美元的纪录。</p>\n<p>隔夜逆回购使用规模创纪录的同时，将美国债务上限提高2.5万亿美元的法案已经获得议会通过，并将交由总统拜登签署。该法案将允许财政部补充已耗尽的现金储备，并消除政府债券违约的风险。</p>\n<p>据报道，拜登将于周四签署该法案。</p>\n<p>随着机构对存放短期现金的需求增加，今年美联储逆回购工具的使用规模飙升。政府现金余额下降以及对突破债务上限的担忧也起到了推波助澜的作用。</p>","source":"sina","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>外媒头条：美联储官宣加速Taper！暗示明年加息三次</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n外媒头条：美联储官宣加速Taper！暗示明年加息三次\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-16 05:34 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/usstock/c/2021-12-16/doc-ikyakumx4410594.shtml><strong>市场资讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>全球财经媒体昨夜今晨共同关注的头条新闻主要有：\n\n1、美联储维持利率不变 宣布加速Taper 点阵图显示明年加息三次\n\n\n2、Omicron加速蔓延 英国Covid病例创下纪录高点\n\n\n3、美国11月零售销售增幅低于预期 表明高通胀正在抑制消费\n\n\n4、全球债务达到创纪录226万亿美元 IMF担心利率上升带来可持续性风险\n\n\n5、美国证券交易委员会计划收紧企业高管的股票出售规定\n\n\n6、美联储隔夜...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2021-12-16/doc-ikyakumx4410594.shtml\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/123472eab1159c5e881f8e540a346014","relate_stocks":{"161125":"标普500","513500":"标普500ETF","DDM":"道指两倍做多ETF","TQQQ":"纳指三倍做多ETF","QQQ":"纳指100ETF","DJX":"1/100道琼斯","UDOW":"道指三倍做多ETF-ProShares","UPRO":"三倍做多标普500ETF","BK4534":"瑞士信贷持仓","SH":"标普500反向ETF","QID":"纳指两倍做空ETF","SSO":"两倍做多标普500ETF","DOG":"道指反向ETF","SPXU":"三倍做空标普500ETF","IVV":"标普500指数ETF","OEF":"标普100指数ETF-iShares","BK4559":"巴菲特持仓","DXD":"道指两倍做空ETF","SQQQ":"纳指三倍做空ETF","BK4550":"红杉资本持仓",".DJI":"道琼斯","QLD":"纳指两倍做多ETF","SPY":"标普500ETF","PSQ":"纳指反向ETF",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index","OEX":"标普100","SDOW":"道指三倍做空ETF-ProShares","BK4504":"桥水持仓","SDS":"两倍做空标普500ETF"},"source_url":"https://finance.sina.com.cn/stock/usstock/c/2021-12-16/doc-ikyakumx4410594.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","article_id":"2191499479","content_text":"全球财经媒体昨夜今晨共同关注的头条新闻主要有：\n\n1、美联储维持利率不变 宣布加速Taper 点阵图显示明年加息三次\n\n\n2、Omicron加速蔓延 英国Covid病例创下纪录高点\n\n\n3、美国11月零售销售增幅低于预期 表明高通胀正在抑制消费\n\n\n4、全球债务达到创纪录226万亿美元 IMF担心利率上升带来可持续性风险\n\n\n5、美国证券交易委员会计划收紧企业高管的股票出售规定\n\n\n6、美联储隔夜逆回购使用规模再创历史新高 达到1.62万亿美元\n\n\n美联储维持利率不变 宣布加速Taper 点阵图显示明年加息三次\n美联储周三向市场提供了多项迹象，表明其自新冠疫情开始以来的超宽松政策即将结束，其举措甚至比市场预期的还要激进。\n美国联邦公开市场委员会（FOMC）当地时间周三公布最新利率决议，将基准利率维持在0%-0.25%区间不变，将超额准备金利率（IOER）维持在0.15%不变，将隔夜逆回购利率维持在0.05%不变，符合市场的普遍预期。\nFOMC声明称，从明年1月起，将每月资产购买规模减少300亿美元，即月度美国国债购买规模降低200亿美元、抵押贷款支持证券（MBS）减少100亿美元，此前为每月减少150亿美元。声明称，委员会认为，可能每月都适合这样减少净购买资产，但如果经济前景发生变化，将准备调整购债速度。\n美联储点阵图显示，所有委员均预计美联储将在2022年开始加息，具体为2022年和2023年分别加息三次。委员们对政策举措持鹰派态度，坚定地倾向于加息。在18名FOMC委员中，12名委员认为明年至少将加息3次，6名预计明年加息不到3次，没有任何委员看到明年利率保持当前近零水平。\n\nOmicron加速蔓延 英国Covid病例创下纪录高点\n英国周三报告了78610例新增新冠病例，为大流行病爆发以来新高，凸显出omicron变异毒株的高传播性。\n之前的纪录高点是在1月8日的68053例，当时英国正处于阿尔法变种引发疫情浪潮、英国进入封锁状态几天之后。\n科研顾问警告称，首相鲍里斯·约翰逊称之为“海啸般的”一波omicron感染浪潮将导致住院人数增加。\n目前尚不清楚疫苗对这种变异毒株有多大效力，不过早期研究表明，两剂疫苗加一剂加强针可以提供针对omicron毒株75%的保护。\n虽然英国的阳性检测结果正在加速增长，但死亡人数远低于大流行病早期的水平。科学家们希望即使在病例数上升的情况下，快速推进加强针的接种能够帮助将重症病例数保持在较低水平。\n\n美国11月零售销售增幅低于预期 表明高通胀正在抑制消费\n美国11月零售销售增幅低于预期，表明在通胀率达到数十年来最高的背景下，消费者正在抑制购物。\n美国商务部周三的数据显示，11月份的总体零售额增长0.3%，10月份的数据向上修正为增长1.8%。不包括汽油和汽车，11月销售额增长0.2%。上述数字没有经过通胀调整。\n媒体调查得出的预测中值显示，经济学家预计11月整体零售额环比增长0.8%。\n弱于预期的报告可能反映了假日销售前移的影响，因为许多知道供应链困难的美国人比平常更早进行假日购物。\n\n全球债务达到创纪录226万亿美元 IMF担心利率上升带来可持续性风险\n国际货币基金组织（IMF）称，全球债务去年飙升至创纪录的226万亿美元，随着利率上升，引发了对债务可持续性的担忧。\nIMF官员周三在一份报告中表示，快于预期的加息可能会给高负债国家带来压力，并迫使政府和企业削减债务和支出，损害经济增长。\n他们援引IMF最新的全球债务数据库称，2020年全球债务/GDP比率上升28个百分点，达到256%，是二战以来升幅最大的一年。\n随着利率上升，财政政策通常会调整，因为政府要拿更多钱还债，并削减支出以控制赤字。\n“如果全球利率上升速度快于预期且经济增长放缓，那么风险将被放大，” Vitor Gaspar牵头的IMF官员写道。“如果公共和私营部门被迫同时去杠杆，增长前景将受到影响。”\n\n美国证券交易委员会计划收紧企业高管的股票出售规定\n长期以来，企业负责人一直被怀疑规避意在防止高层管理人员利用内线消息进行交易的规定。现在，美国证券交易委员会正想办法打击这类交易。\n监管机构正在处理一个争议的问题：什么时候可以允许可能接触到重要非公开消息的公司内部人士出售股票？目前，企业高层主管可以只在抛售股票的前几天拟定出售计划，参议员Elizabeth Warren和其他立法者指出，这使得他们能在发布足以影响股价的公司公告前提前动作。\n美国证券交易委员会官员称，作为回应，该委员会准备提出新规则，迫使公司内部人士在安排出售至真正卖出股票之间等待大约四个月的时间。\n该机构将在周三的会议上就提出新限制措施进行表决。现行法规于20年前制定，旨在帮助高层管理人员出售股票并避免日后被指控进行内线交易。但最近的学术研究显示，股票销售计划充斥着可疑的特定时点交易。证券交易委员会主席Gary Gensler于6月表示，这些与企业相关的政策“导致我们的内线交易规范出现了真正的裂缝”。\n“这项提案解决了我们发现的一些漏洞，”Gensler在计划投票前接受采访时说。“这将有助于增强对资本市场的信任。”\n\n美联储隔夜逆回购使用规模再创历史新高 达到1.62万亿美元\n投资者在美联储一个重要政策工具存放的资金创下历史新高。\n八十五名对手方周三利用隔夜逆回购协议存入美联储的资金达到1.62万亿美元，打破了第三季度最后一个交易日创下的1.605万亿美元的纪录。\n隔夜逆回购使用规模创纪录的同时，将美国债务上限提高2.5万亿美元的法案已经获得议会通过，并将交由总统拜登签署。该法案将允许财政部补充已耗尽的现金储备，并消除政府债券违约的风险。\n据报道，拜登将于周四签署该法案。\n随着机构对存放短期现金的需求增加，今年美联储逆回购工具的使用规模飙升。政府现金余额下降以及对突破债务上限的担忧也起到了推波助澜的作用。","news_type":1},"isVote":1,"tweetType":1,"viewCount":889,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604791287,"gmtCreate":1639444098079,"gmtModify":1639444098174,"author":{"id":"4092093145464560","authorId":"4092093145464560","name":"MrKeith","avatar":"https://static.tigerbbs.com/460dea2188efdfc37ad3bbaf86f6b649","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4092093145464560","authorIdStr":"4092093145464560"},"themes":[],"htmlText":"Very good read. Thanks","listText":"Very good read. Thanks","text":"Very good read. Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604791287","repostId":"1168636209","repostType":2,"isVote":1,"tweetType":1,"viewCount":781,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605062939,"gmtCreate":1639094376045,"gmtModify":1639094376045,"author":{"id":"4092093145464560","authorId":"4092093145464560","name":"MrKeith","avatar":"https://static.tigerbbs.com/460dea2188efdfc37ad3bbaf86f6b649","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4092093145464560","authorIdStr":"4092093145464560"},"themes":[],"htmlText":"Good news to buy?","listText":"Good news to buy?","text":"Good news to buy?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605062939","repostId":"1163135799","repostType":4,"repost":{"id":"1163135799","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639061282,"share":"https://www.laohu8.com/m/news/1163135799?lang=&edition=full","pubTime":"2021-12-09 22:48","market":"us","language":"en","title":"EV stocks fell in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1163135799","media":"Tiger Newspress","summary":"EV stocks fell in morning trading.Tesla,Rivian,Xpeng Motors,Lucid,Fisker,Arrival,Nikola and Canoo fe","content":"<p>EV stocks fell in morning trading.Tesla,Rivian,Xpeng Motors,Lucid,Fisker,Arrival,Nikola and Canoo fell between 1% and 6%.Nio&nbsp;and&nbsp;Li Auto&nbsp;rose slightly.</p>\n<p><img src=\"https://static.tigerbbs.com/c8a11efe3cb20d414d7ebc7c3c40a7eb\" tg-width=\"399\" tg-height=\"719\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV stocks fell in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV stocks fell in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-09 22:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>EV stocks fell in morning trading.Tesla,Rivian,Xpeng Motors,Lucid,Fisker,Arrival,Nikola and Canoo fell between 1% and 6%.Nio&nbsp;and&nbsp;Li Auto&nbsp;rose slightly.</p>\n<p><img src=\"https://static.tigerbbs.com/c8a11efe3cb20d414d7ebc7c3c40a7eb\" tg-width=\"399\" tg-height=\"719\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来","TSLA":"特斯拉","GOEV":"Canoo Inc.","FSR":"菲斯克","LI":"理想汽车","XPEV":"小鹏汽车","NKLA":"Nikola Corporation","FFIE":"Faraday Future","WKHS":"Workhorse Group, Inc.","RIVN":"Rivian Automotive, Inc.","LCID":"Lucid Group Inc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163135799","content_text":"EV stocks fell in morning trading.Tesla,Rivian,Xpeng Motors,Lucid,Fisker,Arrival,Nikola and Canoo fell between 1% and 6%.Nio and Li Auto rose slightly.","news_type":1},"isVote":1,"tweetType":1,"viewCount":684,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}